The Bruton tyrosine kinase inhibitor was approved in combination with bendamustine and rituximab in previously untreated ...
The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback